MG
OTLK icon

Michael Gelband’s Outlook Therapeutics OTLK Stock Holding History

Michael Gelband’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,235
Closed -$60K – 1909
2024
Q3 		$60K Buy
+11,235
New +$82.2K ﹤0.01% 1533
2021
Q2 		– Sell
-7,095
Closed -$319K – 2681
2021
Q1 		$319K Buy
7,095
+5,215
+277% +$200K ﹤0.01% 1625
2020
Q4 		$49K Buy
+1,880
New +$39.3K ﹤0.01% 1873
2020
Q1 		– Sell
-550
Closed -$6K – 1493
2019
Q4 		$6K Buy
+550
New +$12.8K ﹤0.01% 1478

Other funds holding OTLK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Michael Gelband's OTLK Position: Q4 2024 in Review

Michael Gelband sold out of Outlook Therapeutics (OTLK) in Q4 2024, closing a stake of 11,235 shares — an estimated $60K sold.

Michael Gelband first reported a position in OTLK in Q4 2019 and held it in 4 quarters. The position peaked at $319K in Q1 2021. 61 funds tracked by Wall St. Rank hold OTLK as of Q4 2024.

  • Michael Gelband reported no remaining Outlook Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Michael Gelband sold 11,235 Outlook Therapeutics shares in Q4 2024, an estimated $60K.
  • Michael Gelband first reported a position in Outlook Therapeutics in Q4 2019 and held it in 4 quarters.
  • Michael Gelband's Outlook Therapeutics position peaked at $319K in Q1 2021.
  • 61 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.